HIGHLIGHTS H2 FY21 product revenues (unaudited) grew 16% on H2FY20 to $13.8m on a constant currency basis (i.e. eliminating impact…
HIGHLIGHTS Aroa to expand on its own direct field sales presence in the United States market in a move expected…
Read MoreHIGHLIGHTS Aroa’s Myriad™ is further validated in a clinical study and peer-reviewed publication - Journal of Wound Care.Study shows 100%…
Read MoreHIGHLIGHTS The national regulatory authority of India, the Central Drugs Standard Control Organisation (CDSCO), approves Myriad™, Endoform® Natural and Endoform®…
Read MoreHIGHLIGHTS Further validation for Aroa’s MyriadTM from clinical study and peer-reviewed publication in Journal of Wound Care.Study shows high success…
Read MoreHIGHLIGHTS Further validation gained for Aroa’s proprietary Endoform® platform with peer-reviewed publication in PLOS ONE.Study provides further insights on the…
Read MoreHIGHLIGHTS CE Mark to allow commercialization of Aroa’s Myriad™ product in the EUMyriad™ is designed for dermal soft tissue reconstruction…
Read MoreHIGHLIGHTS U.S. FDA clearance received for a new Aroa Biosurgery product Symphony™, designed to support healing during the proliferative phase…
Read MoreAuckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the Australian Securities Exchange (ASX) as…
Read MoreSan Diego, U.S. Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are…
Read More